Legacy AI grade · Sources dated 2026-06-09. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow

Vitamin B12 for Masld

Verdict: Counter-Evidence

Across 6 PubMed studies, the evidence for Vitamin B12 in Masld grades Tier D — counter-evidence. High-quality evidence indicates it is not effective (or is harmful) for this use.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
90%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.465
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Bi-directional causal effect between vitamin B12 and non-alcoholic fatty liver disease: Inferring from large population data
PMID: 36950332 2023 Cohort n = 45,576
Finding: Genetically predicted higher vitamin B12 was associated with INCREASED NAFLD risk (combined OR 1.30, 95% CI 1.13-1.48, p<0.001 per SD), with reverse causality also seen (NAFLD liability raised B12, beta 0.08, p=0.034).
Effect size: OR 1.30 (95% CI 1.13-1.48) per SD increase in B12
View on PubMed
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial
PMID: 35982162 2022 RCT (double-blind) n = 40
Finding: B12 significantly lowered the surrogate marker homocysteine vs placebo (median -2.1 vs -0.003 umol/L, p=0.038), but between-group differences in liver steatosis, ALT and fasting glucose were NOT significant.
🟠 Limited quality Academic Effect size: Homocysteine change -2.1 vs -0.003 umol/L (p=0.038); no significant between-group change in steatosis/ALT
View on PubMed
Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial
PMID: 39202647 2024 RCT (double-blind) n = 196
Finding: The B12-containing cocktail reduced CAP by 4% and TE by 7.8% vs placebo (both p<0.05), but B12 was co-administered with folate, betaine, omega-3 and choline so its independent effect cannot be isolated.
🟠 Limited quality Government Effect size: CAP -4% (p<0.05); TE -7.8% (p<0.05) for combined cocktail
View on PubMed
Associations of serum folate and vitamin B12 levels with all-cause mortality among patients with metabolic dysfunction associated steatotic liver disease: a prospective cohort study
PMID: 39703860 2024 Cohort n = 2,125
Finding: Higher serum B12 was associated with LOWER all-cause mortality (Q3 HR 0.58, 95% CI 0.39-0.86, p=0.008; Q4 HR 0.72, 95% CI 0.54-0.96, p=0.026), but this is observational and likely confounded by reverse causation (low B12 marking sicker patients).
Effect size: Q3 HR 0.58 (0.39-0.86); Q4 HR 0.72 (0.54-0.96) vs lowest quartile
View on PubMed
The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004
PMID: 35334881 2022 Cross-sectional n = 8,397
Finding: Functional B12-pathway markers were associated with advanced fibrosis (homocysteine OR 2.76, 95% CI 1.49-5.11; methylmalonic acid OR 1.41, 95% CI 1.10-1.80), indicating impaired B12 metabolism tracks with worse disease rather than B12 being protective.
Government Effect size: Homocysteine OR 2.76 (1.49-5.11); MMA OR 1.41 (1.10-1.80) for advanced fibrosis
View on PubMed
The Role of Vitamins in Non-Alcoholic Fatty Liver Disease: A Systematic Review
PMID: 34522493 2021 系統性回顧 n = 17
Finding: Narrative review of 17 studies concluded vitamin deficiency associates with NAFLD and that B12 shows 'promise', but found no quantitative pooled effect and explicitly stated more well-designed human trials are needed.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Supportive
a cause and effect relationship has been established source↗
L4c UK NHS
Supportive
Adults aged 19 to 64 need about 1.5 micrograms a day of vitamin B12. source↗
L4d TW TFDA / 衛福部
Supportive
維生素B12之足夠攝取量(AI)成人為每日2.4微克 source↗
L4e WHO
Supportive
Vitamin B12 or folate supplementation during pregnancy is not recommended as an intervention to improve maternal and infant health outcomes source↗
L5a NIH Office of Dietary Supplements
Supportive
Vitamin B12 supplementation appears to have no beneficial effect on performance in the absence of a nutritional deficit. source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-masld-INT-vitamin-b12-001 繁體中文版 →